COMP <GO>
AGIO vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Agios Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AGIO 3
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: AGIO
LAST: $30.55 (-17.94%) • MKT CAP: $2.22B
balance-sheet
11.84
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGIO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.30% | 70.20% | +18.10 | AGIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.80% | 29.00% | -62.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.97% | 3.47% | -20.44 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 48.00% | 8.60% | +39.40 | AGIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 11.84 | 5.33 | +6.51 | AGIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 65.1 | -8.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.22B | $513.86B | -$511.64B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGIO REV | ABBV REV | AGIO GROSS % | ABBV GROSS % | AGIO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $54.0M | $61.16B | 88.3% | 70.2% | -$377.3M | $17.82B |
| FY 2024 | $36.5M | $56.33B | 88.6% | 70.0% | -$391.5M | $17.83B |
| FY 2023 | $26.8M | $54.32B | — | — | -$296.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
ABBV // BETA 1.15